FindTrial
Sign In

Expression of AKAP12, MRE11, SMG7 and other biomarkers in primary and metastatic tumor and their clinical significance

Expression of AKAP12, MRE11, SMG7 and other biomarkers in primary and metastatic tumor and their clinical significance

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023517
Enrollment
Unknown
Registered
2019-06-01
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Case series:no

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. sign the informed consent for surgery; 2. aged <85 years; 3. pathological diagnosis.

Exclusion criteria

Exclusion criteria: 1. accompanied by other malignancies, including concurrent or previously detected malignancies; 2. patients with severe liver, kidney, hematopoietic and nervous system diseases and mental disorders; 3. With history of other malignant tumors; 4. With distant metastasis before surgery; 5. Received neoadjuvant radiotherapy, chemotherapy or endocrine therapy; 6. circumstances where other reviewers have identified grounds for nonconformity from the enrolled study: potential nonconformity with clinical protocol.

Design outcomes

Primary

MeasureTime frame
5-year progression free survival;—

Countries

China

Contacts

Public ContactLin Qing

Shanghai Tenth People's Hospital

Linqing.linda@163.com+86 18917687905

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026